Introduction
============

Diffuse large B-cell lymphomas (DLBCL) are the most common lymphoid malignancies, comprising 35% to 40% of all adult non-Hodgkin lymphomas. This category encompasses all malignant lymphomas characterized by large neoplastic cells and B-cell derivation ([@b43-bmi-2007-403]; [@b76-bmi-2007-403]; [@b79-bmi-2007-403]). DLBCL may develop *de novo* (primary DLBCL) or arise from a previously indolent lymphoma (secondary, transformed DLBCL) at virtually every nodal or extranodal location. It is most commonly observed in cervical, axillar and mediastinal nodes, the stomach and the ileo-coecal region ([@b43-bmi-2007-403]). DLBCL are accompanied by an aggressive clinical presentation with the need for highly effective chemotherapy regimens (e.g. [@b22-bmi-2007-403]). Only about 60% of patients can be cured by rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) and equivalent treatment regimens ([@b22-bmi-2007-403]; Mitterlchner et al. 2006). The gold standard of predicting survival and stratifying patients for risk-adjusted therapy is the international prognostic index (IPI) ([@b116-bmi-2007-403]), which consists of easily assessable clinical and laboratory parameters: age, serum lactate dehydrogenase (LDH), stage, performance status and \>1 extranodal sites involved. No such histopathologically-defined parameters exist and although the current World Health Organization (WHO) classification ([@b43-bmi-2007-403]) accepts different morphologic variants and subtypes of DLBCL, their prognostic utility is hampered by a high rate of interobserver variation, which generally minimizes their influence in therapy. In the last decade, extensive studies of the clinical, phenotypic and molecular aspects of DLBCL have identified them as a heterogeneous group of tumors. These studies suggested new disease subtypes and variants with distinct clinical characteristics, morphology, immunophenotypes, genotypes or gene expression profiles associated with distinct prognoses or unique sensitivities to specific therapy regimens ([@b99-bmi-2007-403]; [@b25-bmi-2007-403]; [@b144-bmi-2007-403]; [@b106-bmi-2007-403]; [@b76-bmi-2007-403]; [@b83-bmi-2007-403]; de Paepe and de Wolf-Peeters, 2006; [@b85-bmi-2007-403]). Unfortunately, the reliability and reproducibility of the molecular results remains unclear, and consequently translation into generally accepted standards to predict survival and stratify patients for risk-adjusted therapy has not taken place (for critical remarks see e.g. [@b51-bmi-2007-403]; [@b25-bmi-2007-403]; [@b42-bmi-2007-403]). Technical issues (antibody affinity), lack of standardization of evaluation procedures (definition of cut-off values) and poor study designs (small sample size and collection bias) are the most important factors hindering the efficient clinical translation of these molecular data. From the histopathological standpoint, some of these problems might be resolved by (A) application of monoclonal antibodies and good working fluorescent *in situ* hybridization (FISH) probes, (B) standardized high throughput analysis methods such as tissue microarrays (TMA) ([@b130-bmi-2007-403]), (C) powerful statistical methods and (D) consideration of both biological (tumor-specific) and clinical (patient-specific) parameters on thoroughly characterized study collectives.

Here, we review phenotypic studies on the prognostic significance of protein expression profiles in DLBCL. Furthermore, we reconsidered our own retrospective data on 301 primary DLBCL cases obtained on a previously validated TMA ([@b128-bmi-2007-403]; [@b140-bmi-2007-403]; [@b151-bmi-2007-403]; [@b132-bmi-2007-403]) in light of powerful statistical methods that determine the optimal cutoff values of phenotypic factors for efficient outcome prediction. Since DLBCL with plasma-blastic differentiation and acquired immunodeficiency syndrome-related lymphomas, as well as primary mediastinal B-cell lymphomas, are beyond the scope of our review, we refer to recent overviews on these rare variants ([@b18-bmi-2007-403]; [@b123-bmi-2007-403]; [@b70-bmi-2007-403]; [@b111-bmi-2007-403]).

DLBCL Immunophenotype
=====================

DLBCL are derived from germinal center-(GC) or post-GC B-cells, and probably from extrafol-licularly-activated B-cells ([@b3-bmi-2007-403]; [@b43-bmi-2007-403]; [@b99-bmi-2007-403]; [@b25-bmi-2007-403]; [@b106-bmi-2007-403]; [@b76-bmi-2007-403]). The neoplastic cells usually express a series of antigens encountered on mature B-cells. Classical DLBCL are often CD19^+^, CD20^+^, CD79a^+^, BSAP^+^ ([@b43-bmi-2007-403]; Torlakovich et al. 2002; [@b99-bmi-2007-403]; [@b25-bmi-2007-403]). The leukocyte common antigen (CD45) is absent in about 30% of immunoblastic and anaplastic DLBCL ([@b34-bmi-2007-403]; [@b43-bmi-2007-403]). Some immunoblastic DLBCL, particularly those derived from preterminally-differentiated post-CG B-cells (plasmablastic-, primary effusion- and ALK^+^ DLBCL), often do not express CD20, CD79a and BSAP, but express MUM1, VS38c, CD138, or immunoglobulin (Ig) heavy or light chains ([@b27-bmi-2007-403]; [@b28-bmi-2007-403]; [@b43-bmi-2007-403]; [@b18-bmi-2007-403]; [@b123-bmi-2007-403]; [@b111-bmi-2007-403]). Lineage specificity in such cases therefore requires immunohistochemical analysis utilizing a broader marker panel. Importantly, considering B-lineage markers, the rituximab era highlights the importance of assessing CD20-status in DLBCL at primary diagnosis and at every sequential biopsy, since therapeutic efficacy is related to CD20 expression, which exposure to rituximab can abrogate ([@b24-bmi-2007-403]; [@b48-bmi-2007-403]).

Prognostic Significance of Immunophenotypic Cellular Differentiation Markers ([Table 1](#t1-bmi-2007-403){ref-type="table"})
============================================================================================================================

The concept of varying DLBCL histogenesis from GC and non-GC B-cells takes, similar to the Kiel and WHO lymphoma-classification concept, normal B-cell differentiation into consideration, a concept supported by gene expression profiling data ([@b3-bmi-2007-403]; [@b99-bmi-2007-403]; [@b25-bmi-2007-403]; [@b106-bmi-2007-403]; [@b76-bmi-2007-403]). Non-neoplastic GC B-cells have a distinct protein expression profile (bcl-6^+^, CD10^+^, MUM1^−^ and CD44s^weakly+^). The expression of *BCL6* and *MUM1*, both involved in transcription regulation of genes important for lymphocyte activation and cell cycle control, is virtually reciprocal in normal B-cells ([Fig. 1](#f1-bmi-2007-403){ref-type="fig"}) ([@b113-bmi-2007-403]; [@b35-bmi-2007-403]). Protein expression in DLCBL in comparison to non-neoplastic B-cells is more complex ([Fig. 2](#f2-bmi-2007-403){ref-type="fig"}), suggesting deregulation of their gene expression, e.g. *MUM1* and *bcl-6* expression is not exclusive in DLBCL ([@b35-bmi-2007-403]; [@b36-bmi-2007-403]; [@b99-bmi-2007-403]; [@b25-bmi-2007-403]; [@b45-bmi-2007-403]). Expression of each of the mentioned differentiation antigens has been found to be of prognostic significance in DLBCL, but these results remain somewhat controversial.

Bcl-6 is a zinc finger sequence-specific transcriptional repressor specifically expressed on GC B-cells ([@b19-bmi-2007-403]; [@b113-bmi-2007-403]). Approximately 50% of DLBCL express Bcl-6 in a variable proportion of tumor cells ([Fig. 3](#f3-bmi-2007-403){ref-type="fig"} and [4A](#f4-bmi-2007-403){ref-type="fig"}) ([@b118-bmi-2007-403]; [@b63-bmi-2007-403]; [@b4-bmi-2007-403]; [@b99-bmi-2007-403]; [@b14-bmi-2007-403]; [@b23-bmi-2007-403]; [@b25-bmi-2007-403]; [@b20-bmi-2007-403]). Bcl-6 expression in DLBCL may be a signature of a GC differentiation stage of the original B-cell before malignant transformation, or may be turned on due to translocations involving the *BCL6* locus at 3q27 with variable partners of either the *Ig* family or *non-Ig* genes, or due to mutations in the 5′ non-translated regulatory region ([@b147-bmi-2007-403]; [@b74-bmi-2007-403]; [@b148-bmi-2007-403]; [@b97-bmi-2007-403]; [@b65-bmi-2007-403]; [@b118-bmi-2007-403]; [@b17-bmi-2007-403]; [@b16-bmi-2007-403]; [@b36-bmi-2007-403]; [@b96-bmi-2007-403]; [@b92-bmi-2007-403]). It is likely that only co-expression of bcl-6 with CD10 reflects a true GC DLCBL derivation ([@b29-bmi-2007-403]; [@b63-bmi-2007-403]; see Paragraph on expression of CD10). Indeed, bcl-6 and CD10 expression cluster together in DLBCL ([Fig. 3](#f3-bmi-2007-403){ref-type="fig"}). While bcl-6 protein or mRNA expression in DLBCL has been found to predict favorable outcomes by some investigators, this has not been confirmed by others ([@b75-bmi-2007-403]; [@b14-bmi-2007-403]; [@b23-bmi-2007-403]; [@b128-bmi-2007-403]; [@b20-bmi-2007-403]; [@b142-bmi-2007-403]). The same contradictory results have been found for *BCL6* rearrangements, which some authors report to be associated with a favorable outcome and others report no distinct prognostic significance ([@b74-bmi-2007-403]; [@b90-bmi-2007-403]; [@b97-bmi-2007-403]; [@b65-bmi-2007-403]; [@b6-bmi-2007-403]; Jerkeman et al. 2004). This controversy can be explained by the fact that translocations, leading to *non-Ig/BCL6* fusion products, indicate a poor prognosis, while those leading to *Ig/BCL6* fusions do not ([@b2-bmi-2007-403]; [@b133-bmi-2007-403]; [@b92-bmi-2007-403]). *Bcl-6* mutations are probably also associated with distinct outcomes in DLBCL ([@b138-bmi-2007-403]; [@b4-bmi-2007-403]).

CD10 is a membrane metalloproteinase expressed in GC B-cells ([@b115-bmi-2007-403]; [@b63-bmi-2007-403]). Approximately 35% of DLBCL express CD10 ([Fig. 3](#f3-bmi-2007-403){ref-type="fig"} and [4B](#f4-bmi-2007-403){ref-type="fig"}) ([@b29-bmi-2007-403]; [@b63-bmi-2007-403]; Fabiani et al. 2002; [@b53-bmi-2007-403]; [@b128-bmi-2007-403]; [@b45-bmi-2007-403]), but the prognostic relevance of such expression is controversial. Some authors reported an association of the CD10^+^ phenotype with a significantly lower rate of complete remissions, but most studies showed CD10 expression to be a favorable prognostic factor in DLBCL ([@b145-bmi-2007-403]; Oshima et al. 2001; [@b134-bmi-2007-403]; Fabiani et al. 2002; [@b23-bmi-2007-403]; [@b12-bmi-2007-403]; [@b86-bmi-2007-403]). A large proportion of CD10^+^ DLBCL express Bcl-6 ([Fig. 3](#f3-bmi-2007-403){ref-type="fig"}), indicating a GC-origin, and this phenotype seems to be particularly predictive of a favorable outcome ([@b103-bmi-2007-403]; [@b7-bmi-2007-403]; [@b23-bmi-2007-403]; [@b52-bmi-2007-403]; [@b77-bmi-2007-403]; [@b128-bmi-2007-403]; [@b20-bmi-2007-403]; [@b45-bmi-2007-403]; [@b151-bmi-2007-403]; [@b10-bmi-2007-403]; [@b135-bmi-2007-403]).

In normal B-cells, MUM1/IRF4 expression probably drives the final steps of intra-GC B-cell differentiation and initiates subsequent steps of maturation towards plasma cells. Thus, MUM1 can be detected by immunohistochemistry in a small percentage of Bcl-6^−^ GC B-cells, post-GC B-cells and plasma cells ([@b35-bmi-2007-403]). In DLBCL, MUM1 is expressed in 50 to 75% of both Bcl-6^+^ and Bcl-6^−^ samples, and may reflect derivation from B-cells at a late GC or post-GC stage of differentiation ([Fig. 3](#f3-bmi-2007-403){ref-type="fig"} and [4C](#f4-bmi-2007-403){ref-type="fig"}) ([@b35-bmi-2007-403]; [@b125-bmi-2007-403]; [@b87-bmi-2007-403]; [@b99-bmi-2007-403]; [@b20-bmi-2007-403]; [@b45-bmi-2007-403]; [@b108-bmi-2007-403]; [@b151-bmi-2007-403]). Gene expression profile analyses showed that *MUM1* clustered within the group of genes expressed by activated B-cell like DLBCL ([@b3-bmi-2007-403]). Subsequent TMA studies demonstrated that expression of MUM1 in at least 30% of tumor cells was associated with a significantly worse outcome ([@b20-bmi-2007-403]; [@b45-bmi-2007-403]; [@b132-bmi-2007-403]; [@b86-bmi-2007-403]; [@b135-bmi-2007-403]), while other studies found no association between MUM1 expression and outcome ([@b23-bmi-2007-403]; [@b10-bmi-2007-403]).

FOXP1 (FORKHEAD BOX P1) is a transcription factor containing a forkhead DNA-binding domain (Kaestner et al. 2000). The *FOXP1* gene is located on chromosome 3 and is expressed in normal activated B-cells and in a subset of DLBCL with a predominantly non-GC phenotype ([Fig. 3](#f3-bmi-2007-403){ref-type="fig"}) ([@b9-bmi-2007-403]; [@b45-bmi-2007-403]; [@b5-bmi-2007-403]; [@b143-bmi-2007-403]). FOXP1 expression correlates with poor survival in DLBCL patients ([@b9-bmi-2007-403]; [@b5-bmi-2007-403]). Interestingly, FOXP1 can be also detected in marginal zone B-cell lymphomas. Studies on the molecular mechanisms underlying FOXP1 expression in both DLBCL and MZL showed that its expression can result from a translocation t(3;14) (p13; q32) in 1% of cases, or may be related to an increased gene copy number, since 60% of FOXP1^+^ DLBCL harbor the trisomy 3 ([@b143-bmi-2007-403]; [@b37-bmi-2007-403]). Interestingly, 45% of FOXP1^+^ extranodal marginal zone B-cell lymphomas also have trisomy 3, and FOXP1 expression correlates with poor survival ([@b109-bmi-2007-403]).

CD44 is a family of cell surface adhesion glyco-proteins that act as receptors for hyaluronate. CD44 molecules play a key role in normal lymphocyte development, homing and activation and are important for tumor spread ([@b57-bmi-2007-403]). CD44 exist in a variety of alternatively spliced isoforms. Normal lymphocytes express the standard CD44 isoform (CD44s). In addition to CD44s, DLBCL may express larger splicing variants (CD44v), especially those containing exon v6/7, which are associated with disseminated malignancies in experimental models ([@b31-bmi-2007-403]). Expression of CD44s and/or CD44v6 has been associated with shortened survival in DLBCL and clustered in bcl-6^−^ (non-GC) cases ([@b104-bmi-2007-403]; [@b30-bmi-2007-403]; [@b54-bmi-2007-403]; [@b128-bmi-2007-403]).

A few studies point to the CD5 expression in DLBCL ([@b47-bmi-2007-403]; [@b66-bmi-2007-403]; [@b122-bmi-2007-403]). Its finding in 109 *de novo* cases was supposed to represent a unique subgroup of DLBCL because of the uniform phenotype (CD5^+^/CD10^−^/CD19^+^/CD20^+^/CD21^+^/CD23^−^/cyclin D1^−^), usual centroblastic morphology and aggressive clinical behavior ([@b146-bmi-2007-403]; [@b122-bmi-2007-403]). However, the putative adverse prognostic relevance of CD5 expression has not been confirmed by other studies, which instead correlated CD5 positivity to the occurrence of other specific molecular aberrations (Katzenberger et al. 2002; [@b60-bmi-2007-403]; [@b150-bmi-2007-403]; [@b149-bmi-2007-403]).

VS38c and CD138 are markers of late post-GC differentiation and are often expressed in HIV-associated-, plasmablastic-, primary effusion- and ALK^+^ lymphomas ([@b27-bmi-2007-403]; [@b28-bmi-2007-403]; [@b43-bmi-2007-403]; [@b18-bmi-2007-403]; [@b123-bmi-2007-403]; [@b70-bmi-2007-403]). Common DLBCL are rarely reactive with these markers ([@b99-bmi-2007-403]; [@b53-bmi-2007-403]).

Considering the expression of bcl-6, CD10 and MUM1 as well as CD44, CD138, bcl-2 and other biomarkers, different algorithms to identify GC and non-CG DLBCL have been proposed (e.g. [@b7-bmi-2007-403]; [@b23-bmi-2007-403]; [@b128-bmi-2007-403]; [@b20-bmi-2007-403]; [@b45-bmi-2007-403]; [@b151-bmi-2007-403], [@b132-bmi-2007-403]; [@b86-bmi-2007-403]; [@b91-bmi-2007-403]; [@b135-bmi-2007-403]), but confirming the relevance of most of them is hampered by failures in results reproducibility and low validity.

Prognostic Significance of Immunophenotypic Cell Cycle-and Apoptosis-controlling Proteins in DLBCL ([Table 1](#t1-bmi-2007-403){ref-type="table"})
==================================================================================================================================================

Disruption of the physiological balance between cell proliferation and cell death is a universal feature of malignant tumors. Two major concurrent regulatory pathways control the cell cycle: The *p53* pathway, which regulates apoptosis and arrest in the G~1~-phase of the cell cycle, and the retinoblastoma (Rb) pathway, which regulates the G~1~-S transition. Cell cycle progression is regulated by a complex molecular network involving cyclins (CCN), cyclin-dependent kinases (CDK) and CDK inhibitors (CDKI). Genetic alterations and/or deregulations of many of these factors are frequently detected in DLBCL ([@b114-bmi-2007-403]).

*p53,* one of the most frequently mutated genes in human cancer, monitors DNA integrity by arresting cells at the G~1~-phase or programming them to cell death when DNA is defective ([@b120-bmi-2007-403]). *p53* is usually immunohistochemically undetectable in normal cells because of its rapid degradation. Missense mutations of *p53* usually result in protein stabilization, making it detectable by immunohistochemistry, but the absence of *p53* expression cannot be regarded as an unequivocal sign of a wild-type gene, since rare nonsense or frameshift mutations produce rapidly degradable *p53* proteins that fail to accumulate ([@b121-bmi-2007-403]). In DLBCL, *p53* is immunohistochemically detectable in 30 to 40% of cases, but only a fraction of *p53*^+^ DLBCL have an underlying mutation, thus *p53* mutational status can obviously not be deduced from immunohistochemically detected *p53* expression alone. Importantly, only *p53* mutations, which are found in about 20% of DLBCL, appear to be associated with clinical drug resistance and poor outcome (Villuendas et al. 1993; [@b100-bmi-2007-403]; [@b64-bmi-2007-403]; [@b53-bmi-2007-403]; Koduru et al. 1997; [@b141-bmi-2007-403]; [@b80-bmi-2007-403]; [@b73-bmi-2007-403]; [@b69-bmi-2007-403]; [@b62-bmi-2007-403]). The combined analysis of *p53* and its downstream target, p21, comprises the distinction between *p53* immunopositivity associated with *p53* mutation (*p53*^+^/p21^−^) and that, reflecting accumulation of wild-type *p53* (*p53*^+^/p21^+^) (Villuendas et al. 1993; [@b21-bmi-2007-403]; [@b80-bmi-2007-403]). Some studies showed that the *p53*^+^/p21^−^ (Δ*p53*) immunophenotype, used as a surrogate for *p53* mutations, is associated with treatment failure and poor survival in DLBCL as well, particularly in GC DLBCL ([@b80-bmi-2007-403]; Pagano et al. 2001; [@b137-bmi-2007-403]). We recently performed a TMA-based study on 297 DLBCL considering the prognostic significance Δ*p53* ([@b140-bmi-2007-403]), which was found in 21% of cases. In a multivariate model, high IPI and Δ*p53* were independent prognostic markers of poor survival.

Bcl-2, a mitochondrial inner membrane anti-apoptotic protein ([@b50-bmi-2007-403]), should be particularly discussed, because its prognostic importance in DLBCL has been confirmed by numerous studies (Moni et al. 1999; [@b101-bmi-2007-403]; [@b117-bmi-2007-403]) and bcl-2 associated treatment resistance can be abolished by the addition of rituximab to CHOP-therapy regimens ([@b84-bmi-2007-403]; [@b22-bmi-2007-403]). Bcl-2 is widely expressed in normal lymphoid tissues, but is absent in GC B-cells ([@b98-bmi-2007-403]). The exemplary t(14;18) (q32; q21) translocation characteristic of follicular lymphoma ([@b126-bmi-2007-403]), which induces production of high levels of bcl-2 protein, is observed in about 25% of DLBCL, but bcl-2 protein expression is found in \>50% of DLBCL ([Fig. 3](#f3-bmi-2007-403){ref-type="fig"}) ([@b58-bmi-2007-403]; [@b100-bmi-2007-403]; Dalla-Favera et al. 1994; [@b40-bmi-2007-403]; [@b97-bmi-2007-403]; [@b65-bmi-2007-403]; [@b118-bmi-2007-403]; [@b101-bmi-2007-403]; [@b52-bmi-2007-403]; [@b77-bmi-2007-403]; [@b53-bmi-2007-403]; [@b8-bmi-2007-403]; [@b128-bmi-2007-403]; [@b55-bmi-2007-403]). Indeed, in the absence of BCL-2 translocation, amplification of 18q21 (containing the BCL2 gene) is another important mechanism for bcl-2 protein over-expression in DLBCL, and can be detected in about 30% of cases ([@b82-bmi-2007-403]; [@b102-bmi-2007-403]; [@b118-bmi-2007-403]; [@b101-bmi-2007-403]). Amplifications seem to be more frequent in non-GC DLBCL (18%) than GC DLBCL (5%), while the latter more frequently harbor the t(14;18) (q32; q21) ([@b52-bmi-2007-403]; [@b77-bmi-2007-403]; [@b105-bmi-2007-403]; [@b8-bmi-2007-403]; [@b55-bmi-2007-403]; [@b67-bmi-2007-403]). There is no evidence that the presence of a BCL-2 translocation at diagnosis has any impact on the survival of patients with DLBCL, though the prognostic impact of bcl-2 protein expression, evaluated in multiple large-scale trials, is significant ([@b49-bmi-2007-403]; [@b40-bmi-2007-403]; [@b97-bmi-2007-403]; Bebb et al. 2002; [@b86-bmi-2007-403]). A recent publication supported the prognostic significance of t(14,18) in GC DLBCL ([@b8-bmi-2007-403]), while others suggest that bcl-2 expression may be of greater prognostic significance in non-GC DLBCL ([@b56-bmi-2007-403]). The anti-apoptotic activity of bcl-2 is modulated in part by its ability to heterodimerize with bax, another member of the bcl-2 protein family with a pro-apoptotic activity ([@b94-bmi-2007-403]). In two studies, low bax expression tended to be correlated with an adverse outcome in DLBCL ([@b41-bmi-2007-403]; [@b119-bmi-2007-403]).

Survivin is a member of the apoptosis-inhibiting protein family and is expressed during mitosis, inhibiting apoptosis at the G~2~-M transition ([@b71-bmi-2007-403]). It is normally undetectable in adult tissues. In a large prospective DLBCL trial, survivin expression was detected in 60% of the cases and was an independent predictor of decreased survival ([@b1-bmi-2007-403]). A second smaller study confirmed these observations for both phenotypical GC- and non-GC DLBCL ([@b139-bmi-2007-403]).

The monoclonal anti-Ki-67 antibody (MIB-1), which detects a protein expressed in the G~1~-, S-, G~2~- and M- but not G~0~-phases of the cell cycle, is widely used as a proliferation marker ([@b15-bmi-2007-403]). The functional significance of Ki-67 remains unclear ([@b112-bmi-2007-403]). In DLBCL, the cell cycle fraction assessed by Ki-67 is variable, usually ranging from 30 to 100%, but is typically high ([@b53-bmi-2007-403]). A high proliferation index has been associated with an unfavorable clinical outcome in some studies, but not in others ([@b78-bmi-2007-403]; [@b73-bmi-2007-403]; personal observations, ([Fig. 3](#f3-bmi-2007-403){ref-type="fig"})). Since it has been suggested that Ki-67 plays a role in the ribosome biosynthesis rather than being directly responsible for cell proliferation ([@b112-bmi-2007-403]), detecting markers directly involved in DNA replication might be a more precise method to evaluate the proliferative behavior of a tumor. The minichromosome maintenance (MCM) protein family, consisting of six abundant members of DNA-binding proteins, stands at the end of many signaling pathways involved in cell proliferation. MCMs ensure that synthesis of DNA is initiated only once during each cell cycle and are only expressed in cycling, but not in quiescent and differentiating cells ([@b127-bmi-2007-403]). We recently demonstrated that expression of MCM2 in ≥40% of tumor cells is a negative prognostic marker for disease-specific survival in a large series of DLBCL ([@b88-bmi-2007-403]).

In normal cells, transition through the restriction point of the cell cycle in the G~1~-phase, beyond which cell proliferation is independent of external signaling, is negatively regulated by the Rb protein, which binds and inactivates E2F transcription factors whose activity is necessary for expression of S-phase genes. Under mitogenic stimulation, accumulation of D-type CCNs allows formation of active CDK4/CCND complexes that inactivate Rb, thus promoting E2F-mediated transcription and subsequent progression through the early (mitogen-dependent) G~1~-phase of the cell cycle. Later, CDK2/CCNE complexes drive the mitogen-independent G~1~-phase progression as well as the G~1~-S transition. CDK1/CCNB1 complexes play an important role in G~2~-M transition and execution of mitosis ([@b114-bmi-2007-403]). Considering cell cycle regulation in DLBCL, expression of CCNB1, CCND2, CCND3, CCNE, CDK1 and CDK2 and CDKI p27 have been shown to be prognostically relevant ([@b32-bmi-2007-403]; [@b107-bmi-2007-403]; [@b110-bmi-2007-403]; [@b38-bmi-2007-403]; [@b81-bmi-2007-403]; [@b39-bmi-2007-403]; [@b68-bmi-2007-403]; [@b72-bmi-2007-403]; [@b108-bmi-2007-403]; [@b46-bmi-2007-403]; [@b89-bmi-2007-403]; [@b132-bmi-2007-403]). Expression of CCND2 in more than 30% or of CCND3 in more than 50% of neoplastic cells, respectively, seems to predict inferior overall survival ([@b39-bmi-2007-403]; [@b45-bmi-2007-403] and [@b46-bmi-2007-403]). In addition to the direct activation of CDK4, CCND3 can further promote cell proliferation by the sequestration of p27 and indirect activation of CDK2/CCNE, which might explain why high p27 expression (probably sequestered by CCND3) is an adverse prognostic factor in DLBCL ([@b107-bmi-2007-403]; [@b110-bmi-2007-403]; [@b72-bmi-2007-403]). We recently showed that 35% of DLBCL express CCNE in \>20% of tumor cells ([Fig. 4D](#f4-bmi-2007-403){ref-type="fig"}) despite the general lack of CCNE gene amplification ([@b132-bmi-2007-403]), a constellation similar to that in classical Hodgkin lymphoma ([@b129-bmi-2007-403]). In classical Hodgkin lymphoma, CCNE over-expression seems to reflect profound deregulation of the cell cycle in Hodgkin and Reed-Sternberg cells ([@b129-bmi-2007-403]; [@b131-bmi-2007-403]) and has no prognostic significance, while CCNE in DLBCL obviously preserves its oncogenic potential to promote G~1~-S transition independent of extracellular mitogenic stimuli ([@b44-bmi-2007-403]; [@b13-bmi-2007-403]). CCNE expression in \>20% of tumor cells is an IPI-independent prognostic factor for both overall- and disease-specific survival and a predictive factor for poor response to CHOP treatment regimens in DLBCL ([@b132-bmi-2007-403]). Expression of CCNE did not correlate with proliferation as assessed by Ki-67 ([@b132-bmi-2007-403]), in agreement with previous observations ([@b32-bmi-2007-403]). Thus, mitogen-independent deregulation of the G~1~-S transition possibly plays a more important oncogenic role than proliferative activity. Interestingly in that context, we and others demonstrated that detection of \>1% CCNB1 stainable cells in DLBCL is also a stage-independent negative prognostic factor ([@b68-bmi-2007-403]; [@b89-bmi-2007-403]). In summary, deregulation of the G~1~-S (CCNE/CDK2) and G~2~-M transitions (CCNB1/CDK1) are probably most critical for the malignant potential of DLBCL ([Fig. 5](#f5-bmi-2007-403){ref-type="fig"}).

Implementation of Receiver Operating Characteristic (ROC) Curves and Area Under ROC (AUROC) to Determine Optimize Prognostic Cut-Off Values of Immunophenotypic Markers in DLBCL
================================================================================================================================================================================

One of the main obstacles for practical translation of the marker profiles reviewed herein is the considerable variation in criteria used by different investigators to classify positive and negative cases, as well as the fact that in some instances (e.g. Bcl-2 and Bcl-6), the multiple mechanisms driving protein expression have not been taken into consideration. The quantity of positive cells and staining intensity for many of the phenotypic markers considered shows a continuous distribution from 0 to 100% in DLBCL. Cut-off levels for the different markers have a broad range and their sensitivity and specificity have not yet been critically addressed ([Table 1](#t1-bmi-2007-403){ref-type="table"}).

When a diagnostic test is based on a continuous variable, a range of different cut-off values may be investigated to decide which value should be used to discriminate between patients according to outcome ([@b11-bmi-2007-403]). In most instances, it is desirable to choose a test that has highest possible values for both sensitivity and specificity. A graphic of sensitivity against 1 -- specificity is called a receiver operating characteristic (ROC) curve ([Fig. 6](#f6-bmi-2007-403){ref-type="fig"}). A perfect test would have a sensitivity and specificity both equal to 1. The ROC curve would start at coordinates X0; Y0, go vertically up the y-axis and then horizontally across to coordinates X1; Y1. A good test would be somewhere close to this ideal ([@b11-bmi-2007-403]). If a variable has no diagnostic or prognostic value, then a test based on it would be equally random and the ROC curve would run diagonally ([Fig. 6](#f6-bmi-2007-403){ref-type="fig"}). The performance of a diagnostic variable can be quantified by calculating the area under the ROC curve (AUROC). The ideal test would have an AUROC of 1, whereas a random guess would have an AUROC of 0.5. If there is no particular requirement on the sensitivity and specificity of a test, then the Youden's index (Y) may be used to choose an appropriate cut-off for the descriptive values from the ROC curve:
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The maximum value Y can attain is 1, when the test is perfect. The coordinates from the ROC curve can be easily calculated and sorted by this index. Optimal cut-off values then should be determined with reference to Y nearest to 1. The potentials of implementation of ROC/AUROC for diagnostic purposes in immunohistochemistry have only recently been realized and addressed (e.g. [@b88-bmi-2007-403]; [@b89-bmi-2007-403]; [@b152-bmi-2007-403]).

Taking into consideration these statistic operators, we critically re-evaluated our own TMA series of 301 primary DLBCL ([@b128-bmi-2007-403]; [@b140-bmi-2007-403]; [@b151-bmi-2007-403]; [@b130-bmi-2007-403]; [@b132-bmi-2007-403]) to determine the optimal cut-off values for differentiation-associated antigen expression ([Table 2](#t2-bmi-2007-403){ref-type="table"}). We linked the results to the clinical end-point "disease-related mortality" and critically compared the outcomes obtained considering the cut-off levels form the ROC curves and Y with those suggested in the literature. Comparison of the results linked to disease-related mortality by the Kaplan-Meier method for every factor unequivocally showed the superior discriminating power (increased sensitivity and specificity) of the cut-off levels calculated considering the ROC curves and Y (e.g. Bcl-6, [Fig. 7](#f7-bmi-2007-403){ref-type="fig"}). Furthermore, we compared the results on the molecular classification of our DLBCL series according to the "Hans' algorithm" ([@b45-bmi-2007-403]) using cut-off values of the variables from the original publication and those suggested by the ROC curves and Y. The Kaplan-Meier analysis showed a superior prognostic value of the phenotypic DLBCL classification according to the cut-off values from the ROC curves (data not shown).

Perspectives
============

A high number of strong candidate biomarkers, particularly expressed proteins, that contribute to prognosis in DLBCL have been identified but not yet translated to practical utility mainly because of contradictory reports in the literature resulting from small sample sizes, referral and selection biases, and variable methodologies and cut-off levels used to determine positivity. These obstacles must be addressed before these biomarkers can be introduced into clinical practice. First, biomarker assessment in DLBCL should be standardized and validated applying powerful statistical methods. Second, the clinical material required to study such questions should be clearly documented and brought into TMAs, which should become an integral part of all clinical trials. The combination of tumor-specific biomarkers with patient-specific clinical factors in new predictive and prognostic models will enable successful individual risk-adjusted patient treatment.

![Reciprocal expression of Bcl-6 (left) and MUM1 (right) in normal germinal centers. Note striking Bcl-6 nuclear positivity in the centroblast-rich follicle dark zone and the majority of cells in the centrocyte-rich pale zone on the left as well as isolated MUM1^+^ cells within the germinal center on the right.](bmi-2007-403f1){#f1-bmi-2007-403}

![Cluster center analysis in our own series of diffuse large B-cell lymphomas considering expression of differentiation markers. The overlap of the red and green ellipsoids with the protein expression circles indicates cluster center tendency. Note the strict segregation of CD10- and MUM1 expression, but the comparatively low segregation of Bcl-6- and CD44s- and even lower Bcl-2- and FOXP1 expression within the diffuse large B-cell lymphoma clusters.](bmi-2007-403f2){#f2-bmi-2007-403}

![Outcome cluster analysis of phenotypic markers and phenotypes according to the "Hans' algorithm" ([@b45-bmi-2007-403]) and cut-off values from [Table 2](#t2-bmi-2007-403){ref-type="table"}, as well as clinical parameters in diffuse large B-cell lymphomas (DLBCL). Cases expressing markers higher than the cut-offs, males, and patients \>66 years are indicated in red, while negative cases, females, and individuals \<66 are in green. Phenotypic germinal center DLBCL are indicated in orange, while non-germinal center DLBCL are in blue; only one DLBCL case (brown) co-expressed all three CD10, Bcl-6 and MUM1. Note the aggregation of FOXP1^+^, MUM1^+^ and Bcl-2^+^ cases in the lymphoma-related deaths cluster as well as the slight predominance of CD10^+^, Bcl-6^+^ and highly proliferative tumors in the survival cluster. Empty balks represent analysis failure or lacking LDH data.](bmi-2007-403f3){#f3-bmi-2007-403}

![**A.** Expression of Bcl-6 in diffuse large B-cell lymphoma (DLBCL). Note intense and moderate nuclear signals in lymphoma cells as well as internal negative controls (endothelial nuclei). **B.** Expression of CD10 in DLBCL. Note intense membranous signals in lymphoma cells as well as internal negative controls (small lymphocytes). **C.** Expression of MUM1 in DLBCL. Note intense and moderate nuclear signals in lymphoma cells. **D.** Expression of cyclin E in diffuse large B-cell lymphoma. Note moderate and isolated intense nuclear signals in lymphoma cells.](bmi-2007-403f4){#f4-bmi-2007-403}

![Schematic demonstration of cell cycle regulation. The most critically disturbed phases in diffuse large B-cell lymphomas are delineated in blue (G~1~-S transition) and red color (G~2~-M transition).](bmi-2007-403f5){#f5-bmi-2007-403}

![Typical receiver operating characteristics (ROC)-curve of a prognostic marker in diffuse large B-cell lymphoma (DLBCL) (blue), in that particular case FOXP1. The area under the ROC-curve is 0.583, p = 0.015, suggesting that FOXP1 determination in DLBCL is of significant prognostic importance. The optimal cut-off value for FOXP1 expression considering survival determined by ROC and Youden's transformation was at 47,5% positivity (arrow) with a specificity of 59% and sensitivity of 57%; note that the cut-off point indicated by the arrow is as next to the coordinates 0.0;1.0. The reference diagonal green line corresponds to a variable without diagnostic capability. The ideal ROC-curve is delineated in red.](bmi-2007-403f6){#f6-bmi-2007-403}

![Comparison of results for the prognostic value of Bcl-6 in our diffuse large B-cell lymphoma series linked to disease-related mortality by the Kaplan-Meier method applying cut-off levels suggested in the literature (upper) and the ROC curves (lower).](bmi-2007-403f7){#f7-bmi-2007-403}

###### 

Review of prognostic phenotypic markers in diffuse large B-cell lymphoma; cut-off levels according to varying reports in the literature. Note the broad range of cut-off levels applied.

  Protein      Outcome[\*](#tfn1-bmi-2007-403){ref-type="table-fn"}   Mechanism                                                             Cut-off[\*\*](#tfn2-bmi-2007-403){ref-type="table-fn"}
  ------------ ------------------------------------------------------ --------------------------------------------------------------------- --------------------------------------------------------
  Bax          favorable                                              reciprocal relationship to Bcl-2                                      \>50%
  Bcl-2        unfavorable                                            anti-apoptosis, drug resistance                                       \>10 to \>50%
  Bcl-6        favorable/uncertain                                    repression of post-GC gene transcription, reciprocal to MUM-1         \>10 to \>30%
  CD5          unfavorable/uncertain                                  distinct cellular origin                                              \>10 to \>20%
  CD10         favorable                                              signature of GC-phenotype                                             \>10 to \>30%
  CD44s & v6   unfavorable                                            tumor dissemination promotion                                         \>20 to \>80%
  CDK1 & 2     unfavorable                                            cell cycle promotion                                                  \>50 to \>80%
  CCNB1        unfavorable                                            facilitation of G~2~-M transition                                     \>1%
  CCND2        unfavorable                                            mitogen-dependent cell cycle progression                              \>30%
  CCND3        unfavorable                                                                                                                  \>5 to \>50%
  CCNE         unfavorable                                            mitogen-independent cell cycle progression, chromosomal instability   \>2 to \>80%
  FOXP1        unfavorable                                            transcriptional repressor in activated B-cells                        \>30 to 100%
  Ki-67        uncertain                                              unknown                                                               \<60, \>50, \>65, \>85%
  Mcm2         unfavorable                                            efficient proliferation                                               \>40%
  Mdm2         unfavorable                                            increased degradation of p53                                          \>10%
  MUM-1        unfavorable                                            promotion of post-GC gene transcription, reciprocal to Bcl-6          \>30%
  p21          probably favorable                                     should be interpreted together with p53                               \>10%
  p27          unfavorable                                            inactivation by CCND3 or SKP2                                         \>5 to \>15%
  p53          unfavorable/uncertain                                  inactivation → lost cell cycle control                                \>5 to \>20%
  pRb          unfavorable                                            inactivation → cell cycle progression                                 \>80%
  SKP2         unfavorable                                            G~1~-S-transition by degradation of p27                               \>60 to \>80%
  Survivin     unfavorable                                            inhibition of apoptosis at G~2~-M                                     \>10%

indicates the mainstream finding of the reviewed studies.

references from which data arose are mentioned in the according manuscript sections dealing with the individual markers.

###### 

Determination of optimal cut-off levels considering disease-specific survival (DSS) for selected phenotypic markers and clinical parameters in our own series of diffuse large B-cell lymphomas applying receiver operating characteristic curves (ROC). The significance of each biomarker considering DSS was finally tested after dichotomization by the Kaplan-Meier (K-M) method. Factors in which values \> cut-off have adverse prognostic effects are italicized.

  Factor    AUROC   p-value^ROC^   Optimal cut-off^DSS^   Sensitivity   Specificity   p-value^DSS(K-M)^
  --------- ------- -------------- ---------------------- ------------- ------------- -------------------
  *Bcl-2*   0.552   0.118          57.5% (60%)            57%           57%           0.082
  Bcl-6     0.542   0.207          14.0% (15%)            49%           64%           0.122
  CD10      0.538   0.199          7.5% (10%)             32%           77%           0.184
  FOXP1     0.583   0.015          47.5% (50%)            57%           59%           0.014
  MUM1      0.513   0.383          64.5% (65%)            52%           79%           0.007
  LDH       0.593   0.027          295 U/L                63%           54%           \<0.001
  Ki-67     0.537   0.195          72.5% (75%)            42%           70%           0.122
  age       0.599   \<0.0001       65.5 (66)              61%           56%           0.005
